Compare UMBF & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UMBF | IBRX |
|---|---|---|
| Founded | 1913 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 7.5B |
| IPO Year | 2006 | 2015 |
| Metric | UMBF | IBRX |
|---|---|---|
| Price | $120.35 | $7.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $138.90 | $12.57 |
| AVG Volume (30 Days) | 469.8K | ★ 21.1M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | 3.34 | ★ 38.71 |
| EPS | ★ 9.29 | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $17.99 | $88.59 |
| Revenue Next Year | $6.55 | $131.15 |
| P/E Ratio | $12.95 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $89.34 | $1.83 |
| 52 Week High | $136.11 | $12.43 |
| Indicator | UMBF | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 62.58 | 48.63 |
| Support Level | $116.18 | $2.25 |
| Resistance Level | $122.37 | $8.28 |
| Average True Range (ATR) | 2.50 | 0.58 |
| MACD | 1.22 | -0.00 |
| Stochastic Oscillator | 86.19 | 47.31 |
UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking services and asset servicing to its customers in the United States and around the world. Its client base includes commercial, institutional, and personal customers. Along with its subsidiaries, the company operates in the following business segments: Commercial Banking, Institutional Banking, and Personal Banking. A majority of its revenue is generated from the Commercial Banking segment, which serves the commercial banking and treasury management needs of small to middle-market businesses through various products and services such as commercial loans, commercial real estate financing, commercial credit cards, letters of credit, loan syndication services, consultative services, and others.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.